GVK BIO to acquire Aragen Bioscience
The deal enables GVK BIO, a small molecule service provider, to expand its service offering to a broader base of organizations, and it gives GVK BIO biologics services and a significant U.S. presence. The acquisition provides Aragen with the ability to expand its service offerings and access to GVK BIO’s global sales force and to new markets. It is GVK BIO’s first international acquisition.
"As an increasing number of biotech and pharmaceutical companies focus on protein-based therapeutics and biosimilars, the acquisition of Aragen Bioscience will strategically enhance GVK BIO’s ability to offer high-quality R&D services to the industry from a seamless integrated platform,” said D. S. Brar, chairman, GVK BIO.